Inhaled Corticosteroid Therapy May Reduce Lung Function Decline in COPD
The adjusted rate of decline in predose trough FEV1 during 52 weeks in the
Researchers used a substudy of the Phase 3 ETHOS study to evaluate lung function decline in patients with inhaled corticosteroid-containing therapies vs glycopyrrolate/formoterol fumarate metered dose inhaler.